Kathryn Piburn
Family · Brandon, MSNPI 1275828030
Payments from drug & device makers
Across 350 payments — averaging $27.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Lilly USA, LLC$1K
- Abbott$499
- Amgen$452
- Boehringer Ingelheim$407
- Corcept Therapeutics$321
- plus $3K from 30 others
What the payments were for
- Travel & lodging$2,42825%
- Food & beverage$7,18375%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 63 | $4,265 |
| Lilly USA, LLC | 66 | $1,056 |
| Abbott | 26 | $499 |
| Amgen | 28 | $452 |
| Boehringer Ingelheim | 24 | $407 |
| Corcept Therapeutics | 14 | $321 |
| Novartis | 16 | $316 |
| AstraZeneca(2 entities) | 12 | $274 |
| Novo Nordisk | 16 | $263 |
| Dexcom, Inc. | 10 | $238 |
| AbbVie | 12 | $194 |
| Radius Health, Inc. | 5 | $153 |
| Bayer | 6 | $132 |
| Xeris Pharmaceuticals, Inc. | 6 | $121 |
| Esperion Therapeutics, Inc. | 6 | $110 |
| Sanofi-aventis U.S. LLC | 5 | $101 |
| Madrigal Pharmaceuticals | 3 | $63 |
| Merck | 3 | $62 |
| Tandem Diabetes Care, Inc. | 3 | $60 |
| Amryt Pharma Holdings Ltd | 3 | $60 |
| Sequel Med Tech, LLC | 3 | $60 |
| Ascendis Pharma Endocrinology Inc | 3 | $51 |
| BD | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $38 |
| Cequr Corporation | 1 | $33 |
| Tersera Therapeutics LLC | 1 | $31 |
| Averitas Pharma Inc. | 1 | $29 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Neurocrine Biosciences, Inc. | 1 | $26 |
| Rhythm Pharmaceuticals, Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $22 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $17 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,646
- MINIMED 780G$932
- SIMPLERA SENSOR$117
- GUARDIAN SENSOR (3)$112
How this compares
$9,622 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 310 | $532,460 |
| MounjaroTirzepatide | 180 | $284,020 |
| JardianceEmpagliflozin | 189 | $240,921 |
| TrulicityDulaglutide | 129 | $196,626 |
| Tresiba Flextouch U-200Insulin Degludec | 177 | $184,628 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $111,009 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 96 | $97,637 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 84 | $86,647 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 55 | $79,926 |
| Tresiba Flextouch U-100Insulin Degludec | 123 | $69,772 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 53 | $69,385 |
| Novolog FlexpenInsulin Aspart | 205 | $54,036 |
| FarxigaDapagliflozin Propanediol | 43 | $49,657 |
| RybelsusSemaglutide | 19 | $44,303 |
| JanuviaSitagliptin Phosphate | 32 | $35,195 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $263 | $661,742398 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,056 | $480,646309 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Trijardy Xr | $407 | $369,338304 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $101 | $97,63796 claims |
| AstraZenecaFarxiga | $274 | $49,65743 claims |
| MerckJanuvia | $62 | $35,19532 claims |
| AbbVieSynthroid | $194 | $1,25711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Brandon
- Karen FreemanBrandon$22K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.